Clinical Trials Arena on MSN3d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Applied Clinical Trials Online2d
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Fierce Pharma4d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Healio1d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback
Promising multiple dose PK data continue to support 4-weekly dosing FDA advice received supporting phase 2 design in HS ...
Applied Clinical Trials Online12d
Beyond the Horizon: A New Era for Faster, Smarter Clinical Trials
Clinical trials are notoriously expensive, with operational expenses ranging from $50 million to over $115 million. 1 The ...
Oncology Nurse Advisor3d
One in Six Patients in Phase 2 Cancer Trials Receive Drug When Eventually Approved
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
Business Wire9d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
mskcc.org25d
In Early-Phase Pancreatic Cancer Clinical Trial, Investigational mRNA Vaccine Induces Sustained Immune Activity in Small Patient Group
New results from the phase 1 clinical trial, now published in the journal Nature, show that the therapeutic cancer vaccine activated tumor-specific immune cells that persisted in the body up to nearly ...